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Abstract
Background: Ensuring long-term adherence to therapy is essential for the success of HIV treatment. As access to viral load
monitoring and genotyping is poor in resource-limited settings, a simple tool to monitor adherence is needed. We assessed
the relationship between an indicator based on timeliness of clinic attendance and virological response and HIV drug
resistance.
Methods: Data from 7 virological cross-sectional studies were pooled. An adherence indicator was calculated as the number
of appointments attended with delay divided by the number of months between antiretroviral treatment (ART) initiation
and date of virological testing and multiplying this by 100. Delays of 1 or more to 5 or more days were considered in turn.
Multivariate random-intercept logistic regression was fitted to examine the effect on outcomes, separately for adults and
children.
Results: A total of 3580 adults and 253 children were included. Adults were followed for a median of 26.0 months (IQR 12.8-
45.0) and attended a median of 24 visits (IQR 13–34). The 1-day delay adherence indicator was strongly associated with viral
load suppression (OR 0.96, 95% CI 0.95–0.97 per unit increase), virological failure (OR 1.05, 95% CI 1.03–1.06) and HIV drug
resistance (OR 1.03, 95% CI 1.01–1.05) after adjusting for initial age and CD4 count, previous ART experience, type of
regimen and Tuberculosis diagnosis at start of therapy. Similar results were observed in children.
Conclusion: An adherence indicator based on timeliness of clinic attendance predicts strongly both virological response
and drug resistance, and could help to timely identify non-adherent patients in settings where viral load monitoring is not
available.
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Introduction
Since the introduction of combined active antiretroviral therapy
(ART), mortality and morbidity due to HIV have been drastically
reduced in high-, middle- and low-income countries [1,2]. ART is
a life-long treatment and the success of therapy is strongly related
to patients achieving and maintaining good levels of adherence to
antiretroviral regimens [3–7]. It is therefore essential to monitor
patient adherence to ART, so as to timely identify poorly adherent
patients, and to develop targeted interventions for optimising and
maintaining adherence levels over time.
Viral load monitoring and genotyping are frequently used to
identify non-adherent patients. However, access to these labora-
tory diagnostics is often poor in resource-limited settings. Simple
alternative tools for rapidly detecting patients who do not regularly
take their antiretroviral drugs as prescribed are therefore urgently
needed [8,9].
No gold standard method exists for assessing treatment
adherence. Many tools have been proposed, including pill-count,
self-reported adherence, various biological markers, attendance to
drug refill visits and/or clinic attendance, and quantitative
determination of drugs in blood [10,11]. Each of these methods
has advantages and drawbacks and some cannot be implemented
routinely by HIV programmes in resource-limited countries
[10,11]. Furthermore, adherence is influenced by many patient-,
time- and treatment-related factors (which also interact with one
another), increasing the complexity of any assessment [12–14].
To monitor the emergence of drug resistance in patients
receiving ART, the World Health Organization (WHO) recom-
mends that HIV programmes use a number of indicators, called
‘‘early warning indicators’’ [15]. One of these is patients’ on-time
appointment-keeping, an indicator we hypothesised might also
correlate with the level of ART adherence and therefore be useful
in predicting adherence behaviour within a patient population.
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To assess whether a simple tool based on regularity of patients’
follow-up clinic attendance can be used as a proxy for treatment
adherence, we pooled data from cross-sectional virological studies
conducted in HIV programmes supported by Me´decins Sans
Frontie`res (MSF), linked them back to longitudinal monitoring
data and examined its relationship with viral load suppression,
virological failure and resistance to antiretroviral drugs.
Methods
Study Design
This is a cross-sectional secondary data analysis of cross-
sectional virological evaluations conducted among patients receiv-
ing ART for 6 months or more in MSF-supported HIV
programmes. Data were linked back to individual patient
monitoring data collected in the HIV programs. Of 11 cross-
sectional studies conducted between 2004 and 2009 in Africa and
Asia, 4 were excluded because virological information was either
unreliable or missing (studies in Zambia, Burkina Faso, Kenya and
Cameroon). Immunovirological testing was done in all studies and
genotype testing in 5 studies (Figure 1). In two studies plasma HIV
RNA quantification was performed using the Cobas Amplicor
HIV-1 Monitor v1.5 reverse transcriptase PCR (Roche Diagnos-
tics, Meylan, France), which targets the gag p24 region of the virus
[16,17]. In the three other studies, the Agence Nationale de
Recherche sur le SIDA et les He´patites Virales (ANRS) generic
real-time PCR test was used [18–20]. The detection threshold for
viral load determination varied from 40 to 400 copies/mL across
studies. Genotyping methods used to identify drug resistance were
the dideoxy chain termination method (ABI PRISM Ready
Reaction AmpliTaq Fs; Dye Deoxy Terminators; Applied
Biosystems, Paris, France) in two studies [16,17] and the standard
methods developed by the ANRS Resistance study group in 3
studies [18–20]. The threshold for genotype testing ranged from
250 to 5000 copies/mL [16–20]. Recommendations were made to
the Epicentre collaborating laboratories to submit the sequence
files from study patients to GenBank.
Routine clinical and laboratory data, such as appointment dates
and the dates of clinic visits, were collected prospectively in each of
the sites using the FUCHIA software (Follow-Up and Care of HIV
Infection and AIDS, Epicentre, Paris). Viral load testing was not
routinely performed in these programs and it was only used when
treatment failure was suspected.
Definitions
In the analyses, viral load suppression was defined as ,400
copies/mL and virological failure as.5000 copies/mL (as defined
in current WHO guidelines [21]). Resistance was defined as the
presence of one or more non-nucleoside reverse transcriptase
inhibitor (NNRTI) or nucleoside reverse transcriptase inhibitor
(NRTI) high-level resistance mutations to antiretroviral drugs,
using the Stanford University’s genotypic resistance database and
test result interpretation algorithm (http://hivdb.stanford.edu/)
[22,23].
In MSF-supported HIV programs, drug refills including
provision of buffer stocks of 1–3 months, usually take place during
clinic visits but antiretroviral drugs are not provided in all medical
visits. In the present study, we used a proxy indicator for patient
adherence to therapy based on the timeliness of patient attendance
to clinic visits [24]. Briefly, we divided the number of appoint-
ments attended with delay by the number of months of follow-up
between the date of ART initiation and the date of virological
testing and multiplied this by 100. Adherence was considered good
if patients were delayed less than 5% of the time in attending their
appointments, moderate if they were delayed attending between
5% and 19% of their appointments, and poor if they were delayed
attending 20% or more of their appointments.
Statistical Analysis
Data were analysed separately for adult ($15 years) and
paediatric (,15 years) patients. Patient characteristics, numbers of
visits, and intervals between consecutive visits during the study
follow-up were summarised using standard descriptive statistics.
Comparison of visits across studies was assessed using Kruskal-
Wallis tests.
Five separate continuous adherence indicators were calculated
for each patient, as explained before, using 1 or more, to 5 or more
days of delay in clinic attendance in turn. Using univariate
random-intercept logistic regression and Wald statistics, we
selected the delay (in number of days) for which the continuous
adherence indicator was most strongly associated with viral load
suppression, virological failure and HIV drug resistance and used
this in subsequent analyses.
Univariate and multivariate random-intercept logistic regression
models were fitted to assess the association between the continuous
and categorical adherence indicators and viral load suppression,
virological failure and HIV drug resistance after adjustment for
other confounding factors at baseline: sex, age, CD4 cell count
(,50, 50–199, $200/mL and unknown for adults; ,200 and
$200/mL for children), WHO clinical stage (1 or 2, 3, 4 and
unknown), body mass index (BMI), tuberculosis diagnosis, history
of ART use and type of regimen (nevirapine and efavirenz for
non-nucleoside reverse transcriptase inhibitor (NNRTI), zidovu-
dine and stavudine for nucleoside reverse transcriptase inhibitor
(NRTI)) at ART initiation.
Two sensitive analyses were performed. First, we did separate
analyses for patients who received ART for ,24 months and for
$24 months. We also repeated the analyses using only data from
the subgroup of patients with complete CD4 cell count, clinical
stage and BMI information.
Statistical analyses were performed with Stata 11.2 software
(Stata Corporation, College Station, Texas, USA).
Ethical Review
Before conducting the cross-sectional studies included in the
analysis, ethics committee approval had been obtained. The ethics
committees for the different studies were: the Uganda National
Council for Science and Technology, the Ugandan AIDS
Research Committee, the National Ethics Committee of Cambo-
dia, KEMRI National Ethical Review Committee of Nairobi
(Kenya), the National Health Science Research Committee of
Malawi and the Consultative Committee for People involved in
Biochemical Research (CPPRB) of Saint Germain-en-Laye, Paris,
France. All participating patients had provided written informed
consent [16–20].
Results
A total of 3840 patients participated in the 7 cross-sectional
studies included in our analysis. Seven patients (0.2%) were
excluded because their date of birth was missing. Of the remaining
3833 patients, 3580 were adults and 253 children.
Patient characteristics at ART initiation are shown in Table 1.
Most patients were treated in Kenyan (39.8%) and Malawian
(35.4%) HIV programmes. Median age for adults was 36.0 years
(interquartile range (IQR) 30.5–42.7) and for children 5.1 years
(IQR 2.7–8.2). About two thirds of adults and half of children were
females; 97% of patients had no history of ART use. Initial median
Clinic Attendance and Virological Outcomes
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e49091
CD4 cell counts were 119 cells/mL (IQR 55–182) and 286 (IQR
178–608), respectively. Fifty-three percent of adults were in clinical
stage 3 and 29.3% in stage 4, median BMI was 19.9 kg/m2 (IQR
18.2–21.8) and 305 patients (8.5%) were diagnosed with tubercu-
losis. Among children, 51% were in clinical stage 3 and 17.4% in
stage 4, median BMI was 14.9 kg/m2 (IQR 13.8–16.2) and 7
patients (2.8%) were diagnosed with tuberculosis. The most
commonly prescribed initial ART regimens were a combination of
stavudine, lamivudine and either nevirapine (83.7% for adults and
91.1% for children) or efavirenz (11.9% and 8.5%, respectively).
Median follow-up time from ART initiation was 26.0 months
(IQR 12.8–45.0) for adults and 22.6 months (IQR 11.1–28.1) for
children. The median numbers of visits per patient were 24 (IQR
13–34) and 17 (IQR 11–24), respectively. Median intervals
between consecutive visits were 0.95 months (IQR 0.82–1.84)
and 1.02 months (IQR 0.89–1.84), respectively, and remained
stable over time on ART (Figure 2).
At the time of the cross-sectional evaluation, 3021 out of 3580
adult patients (84.5%) were virologically suppressed while 248
(6.9%) had virological failure. Genotype testing was performed for
Figure 1. Flow chart of the patients included in the study.
doi:10.1371/journal.pone.0049091.g001
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2205 adult patients who had a viral load .1000 copies/mL. A
total of 123 (5.6%) patients were classified as having HIV drug
resistance to at least one antiretroviral drug. Similarly, 144 out of
253 pediatric patients (56.9%) failed to suppress viral load while 79
(31.2%) had virological failure. Genotype testing was performed
for 33 children who had a viral load .1000 copies/mL. A total of
29 (11.5%) children had HIV drug resistance to at least one
antiretroviral drug. The frequency of profiles of NRTI and
NNRTI mutations encountered is shown in Tables S1 and S2.
The use of the continuous adherence indicator based on a delay
of 1 or more days after the scheduled appointment date showed
the strongest association with viral load suppression, virological
failure and HIV drug resistance in univariate analyses (Wald
statistics of –6.50, 6.32 and 3.13, respectively; data not shown) and
was therefore used in the subsequent risk factor analysis.
The overall proportion of appointments attended with delay
was 6.38% (95% CI: 6.22–6.55%) for adults and 12.08% (95% CI:
11.13–13.07%) for children, and decreased slightly following ART
initiation. The median numbers of appointments attended with
delay per patient were 1 (IQR 0–2) and 2 (IQR 0–3), respectively.
These represent medians of 4.59% (IQR 0–11.11) and 9.09%
(IQR 0–20.0%) of appointments attended with delay per patient,
respectively. Median numbers and proportions of appointments
attended with delay differed across studies (P,0.001).
Association between Adherence and Virological
Outcomes in Adults
The median value of the continuous adherence indicator in the
full dataset was 4.08% (IQR 0–9.06%) and ranged from 0% (IQR
0%–2.01%) to 7.93% (IQR 0%–9.91%) across studies. According
to the study classification, 58.0% of patients showed good
adherence, 35.6% moderate and 6.4% poor. The categorisation
of patients according to adherence levels (categorical indicator)
showed higher proportions of individuals with poor and moderate
adherence among those with virological failure and HIV drug
resistance, and higher proportions of individuals with good
adherence among those with viral load suppression (Figure 3).
In univariate analysis using the continuous adherence indicator,
patients with higher adherence indicator values (e.g. higher
incidence of appointments attended with delay) were less likely
to achieve viral load suppression (Odds Ratio (OR) 0.96, 95% CI
0.95–0.97 per unit increase), and more likely to experience
virological failure (OR 1.05, 95% CI 1.03–1.06) and HIV drug
resistance (OR 1.03, 95% CI 1.01–1.05).
In multivariate analyses (Table 2), the categorical adherence
indicator was strongly associated with viral load suppression (OR
0.70, 95% CI 0.57–0.86 for moderate adherence, and OR 0.35,
95% CI 0.25–0.49 for poor adherence, compared to good
adherence), virological failure (OR 1.86, 95% CI 1.38–2.50 and
OR 3.16, 95% CI 2.01–4.99, respectively) and drug resistance
(OR 1.70, 95% CI 1.07–2.70 and OR 2.54, 95% CI 1.33–4.86,
respectively). Results of random intercept testing were significant
(P,0.001) and variance due to studies represented less than 5% of
the total variance, suggesting low heterogeneity between studies.
Association between Adherence and Virological
Outcomes in Children
In the full dataset, the median value of the continuous
adherence indicator among children was 7.90% (IQR 0–
16.65%). Overall, 43.0% were classified as showing good
adherence, 42.7% as moderately adherent and 14.2% as poorly
adherent. In multivariate analyses, the categorical adherence
indicator remained strongly associated with viral load suppression
(OR 0.59, 95% CI 0.34–1.02 for moderate adherence, and OR
0.35, 95% CI 0.16–0.77 for poor adherence, compared to good
adherence) and with virological failure (OR 2.22, 95% CI 1.20–
4.11 and OR 2.87, 95% CI 1.25–6.61, respectively). A borderline
statistical association was observed for drug resistance despite of
the small sample size (OR 3.14, 95% CI 1.03–9.54, p = 0.04;
Table 2).
Sensitivity Analyses
Sensitivity analyses showed that the adherence indicator
evaluated remained strongly associated with viral load suppression,
virological failure and drug resistance regardless of the duration of
ART in both adults and children. Furthermore, the estimated
effect was similar regardless of the duration of ART (,24 or $24
Table 1. Patient characteristics at ART start by age.
Characteristics Adults (N=3580) Children (N=253)
Site (%)
Study 1, Malawi 1267 (35.4) 81 (32.0)
Study 2, Kenya 924 (25.8) 2 (0.8)
Study 3, Uganda 506 (14.1) 86 (34.0)
Study 4, Kenya 502 (14.0) 84 (33.2)
Study 5, Cambodia 381 (10.7) 0 (0.0)
Age, years
Median [IQR] 36.0 [30.5–42.7] 5.1 [2.7–8.2]
Sex (%)
Men 1293 (36.1) 125 (49.5)
Women 2287 (63.9) 128 (50.5)
History of ART (%)
Yes 108 (3.0) 4 (1.6)
No 3472 (97.0) 249 (98.4)
CD4 cell count, cells/mL
Median [IQR] 119 [55–182] 286 [178–608]
,50 659 (18.4) 16 (6.3)
50–199 1700 (47.5) 47 (18.6)
$200 509 (14.2) 136 (53.8)
Unknown 712 (19.9) 54 (21.3)
Clinical stage (%)
1 or 2 606 (16.9) 64 (25.3)
3 1885 (52.7) 129 (51.0)
4 1047 (29.3) 44 (17.4)
Unknown 42 (1.1) 16 (6.3)
BMI, kg/m2
Median [IQR] 19.9 [18.2–21.8] 14.9 [13.8–16.2]
,18.5 1040 (29.0) 99 (39.1)
$18.5 2502 (69.9) 134 (53.0)
Unknown 38 (1.1) 20 (7.9)
Tuberculosis diagnosis
(%)
No 3275 (91.5) 246 (97.2)
Yes 305 (8.5) 7 (2.8)
Note: BMI, body mass index, categorized for children according to Cole et al.
classification [32].
doi:10.1371/journal.pone.0049091.t001
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months), and analyses restricted to patients with complete data
showed consistent results (data not shown).
Discussion
In this large multicentric cross-sectional study including 3833
patients, we observed a strong association between an ART
adherence indicator based on the regularity of attendance to
scheduled clinic appointments and viral load suppression, virolog-
ical failure and HIV drug resistance. Patients classified as having
lower levels of adherence as defined by our indicator were less
likely to have undetectable HIV viral load and were two to three
times more likely to be in virological failure and have developed
resistance mutations to antiretroviral drugs. These associations
were seen in both adults and children and did not vary with
duration of ART use.
In our study population virological and drug resistance
outcomes were more strongly associated with the adherence
indicator based on a delay of one or more days after the scheduled
clinical visit was used in the calculation. This delay seems
reasonable in the context of HIV treatment programmes in
resource-limited settings. In our study 6% of patient appointments
were attended with a delay of one or more days. Although
previous studies have suggested that adherence might decline with
time on ART [13], in our analysis, both the proportion of
appointments attended with delay and the interval between
successive clinic visits remained almost constant over time since
treatment initiation. The median treatment duration of study
patients was 26 months and 75% of individuals had received
therapy for less than 45 months. These findings seem to support
the validity of using the proposed adherence indicator to monitor
adherence in HIV programmes during the first 3–4 years of ART.
Overall, approximately 57% of patients showed good adherence
when the indicator evaluated was used. This figure is lower than
estimates reported in previous studies conducted in resource-
limited settings, but those studies primarily used self-reported
measures of adherence and a 95% cut-off to define good
adherence [3,25]. Lower estimates of effect have been reported
in studies where objective measurements of adherence, such as a
Medication Event Monitoring System (MEMS), were used [25].
Such objective measurement methods, including delays in clinic
attendance, might discriminate better among patients with
different levels of adherence and could help to identify higher
numbers of non-adherent patients.
The data used for this evaluation included patients from several
African and one Asian HIV programme. At the time of the cross-
sectional evaluations about 85% of study patients were virologi-
cally suppressed, 7% had virological failure and 6% had resistant
mutations to antiretroviral drugs. Despite the relatively low rates of
failure and drug resistance, a high and statistically significant
increase in the probability of these two outcomes was observed in
patients classified by the proposed indicator as moderate or low
adherent, compared with patients classified as good adherent. This
effect was independent of age, previous exposure to ART or the
CD4 cell count level at ART initiation, and of the type of
antiretroviral regimen taken. Although the absence of viral load
monitoring in the study sites did not allow us to distinguish
between episodes of long- versus short-term viremia in the
analyses, our findings are strengthened by the consistent results
of an association between the three virological outcomes studied
and the adherence indicator (considered as either continuous or
categorical variable). These outcomes are key markers of true
adherence and treatment success.
The association between the virological outcomes and the
adherence indicator was also strong in children despite the smaller
Figure 2. Variation in the time between two consecutive visits with length of follow-up since ART initiation in adults (a) and
children (b).
doi:10.1371/journal.pone.0049091.g002
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sample size of this group of patients, and it was of borderline
significance for antiretroviral resistance, probably due to lack of
power. This is an important finding that supports the use of this
same indicator to identify non-adherent adult and children
patients.
We previously described strong associations between the
adherence indicator evaluated, failure to first- and second-line
therapy (primarily defined by WHO clinico-immunological
criteria), and mortality among patients using first- and second-
line therapy [26,27]. Several studies have reported an association
between virological outcomes and attendance to drug-refill visits
and/or clinic attendance [28–31]. However, these studies were
generally smaller in size and/or conducted in a single centre,
limiting the generalisability of the findings. Strengths of our study
are its large sample size, the inclusion of patients coming from
seven different HIV treatment programmes in sub-Saharan Africa
and Southeast Asia, the availability of genotyping drug resistance
data to confirm the results of the evaluation, and the consistent
results found in children and adult patients. The multivariate
mixed model indicated low heterogeneity between the centres
included in the evaluation and supports the use of the indicator in
other sub-Saharan African and Southeast Asian HIV pro-
grammes.
Our study has several limitations. First, patient follow-up on
ART differed greatly according to site, from about 6 to 60 months,
depending on the eligibility criteria used in each cross-sectional
evaluation. As a result, the number of clinic visits per patient
varied widely across sites, which could affect the reliability of the
adherence indicator. To assess whether the duration of follow-up
affects our findings, we performed a sensitivity analysis to identify
possible differences in the degree of association between patients
followed for less than 24 months and those followed for more than
24 months. No evidence of differences was detected for viral
suppression, virological failure or HIV drug resistance. In
addition, the length of delay in clinic attendance was not
considered in the calculation of the indicator. Nevertheless, the
median duration of clinic delay was 3 days and only 3.2% of visits
had delays of more than 5 days.
Our indicator might tend to underestimate patient adherence,
since patients coming for more than one day after their scheduled
visit are considered non-adherent for the entire period between the
last visit and the actual visit, which is probably not the case (buffer
drugs given to patients could prevent treatment interruptions).
Because we calculated the adherence indicator over the whole
period of ART use, we could not assess the temporal relationship
between exposure and outcome and the effect of time itself was not
really taken into account. Nevertheless, the homogeneous distri-
bution of appointments attended with delay over time gives further
confidence in the indicator. For the same reason, another
important finding is that the interval between successive visits
(on average about 1 month) was almost constant over time on
ART.
In conclusion, in this multicentric study conducted in resource-
limited settings we observed a strong association between an
Figure 3. Patient distribution of adherence to clinic visits by outcome in adults (a) and children (b).
doi:10.1371/journal.pone.0049091.g003
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indicator of adherence based on regularity of clinic attendance and
both virological response and drug resistance. This indicator
represents a simple tool that could be used in HIV treatment
programmes for prompt identification of non-adherent patients
who need strong, targeted support and counselling to prevent
virological failure and drug resistance development.
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Table 2. Multivariate random-intercept logistic regressions of experiencing viral load suppression, virological failure and HIV drug
resistance for adults and children.
Factors Viral suppression Virological failure HIV drug resistance
OR (95% CI) OR (95% CI) OR (95% CI)
Adults
Adherence indicator
Good 1 1 1
Intermediate 0.70 (0.57–0.86) 1.86 (1.38–2.50) 1.70 (1.07–2.70)
Poor 0.35 (0.25–0.49) 3.16 (2.01–4.99) 2.54 (1.33–4.86)
Age, years 1.02 (1.01–1.03) 0.96 (0.95–0.98) 0.95 (0.93–0.98)
ART experience
Yes 1 1 1
No 2.22 (1.34–3.68) 0.46 (0.24–0.91) 0.18 (0.08–0.38)
CD4 cell count, cells/mL
,50 1 1 1
50–199 1.06 (0.80–1.39){ 0.76 (0.53–1.08) 0.55 (0.34–0.87)
$200 1.08 (0.75–1.55){ 0.58 (0.37–0.98) 0.66 (0.32–1.39)
Unknown 0.83 (0.60–1.15){ 0.99 (0.66–1.52) 0.89 (0.47–1.67)
NNRTI component of regimen
EFV 1 1 1
NVP 1.61 (1.00–2.60) 0.94 (0.53–1.67){ 0.96 (0.39–2.35){
Tuberculosis diagnosis
No 1 1 1
Yes 1.09 (0.73–1.63){ 0.94 (0.56–1.98){ 1.86 (0.98–3.54)
Children
Adherence indicator*
Good 1 1 1
Intermediate 0.59 (0.34–1.02) 2.22 (1.20–4.11) 3.14 (1.03–9.54)
Poor 0.35 (0.16–0.77) 2.87 (1.25–6.61) -
Sex
Men 1 1 1
Women 1.83 (1.09–3.06) 0.37 (0.21–0.65) 0.74 (0.28–1.95){
CD4 cell count, cells/mL
,200 1 1 1
$200 0.80 (0.43–1.48){ 0.92 (0.48–1.79){ 0.45 (0.17–1.19){
Unknown 1.02 (0.47–2.20){ 0.71 (0.31–1.65){ 1.14 (0.19–6.90){
Note: NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
*Moderate and poor adherence categories were combined in the analysis of HIV drug resistance among children.
{Non-significant factor in the final model.
doi:10.1371/journal.pone.0049091.t002
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